

Accenture: Where Should the Next Investment Go?

Internal ID: S&F-STR-027

Topic: Mergers & Acquisitions, Capital Allocation, Growth Strategy

Industry: IT Consulting & Other Services

Source: Strategy & Finance

Publication date: 5 October 2026

License: Not specified

Student strategy case • Information cutoff: October 3, 2026

On October 1, Accenture reported fiscal 2026 revenue growth of 5% in local currency, \$84.5 billion in bookings, and \$11.6 billion in free cash flow. Management also described a large investment agenda: about \$3 billion of Cybersecurity/Operational Technology (Cyber OT) acquisition capital had shifted from the fourth quarter into the first quarter of FY2027, while the company expected to deploy “another” approximately \$5 billion on acquisitions during FY2027. [C1, pp. 1-2, 6-7; C2, pp. 2-3, 11-13; C5, pp. 4, 7.]

The same disclosures showed multiple ways to invest and return capital. In FY2026, management reported \$4.9 billion across 17 acquisitions, \$1 billion of R&D spending, and \$1 billion in learning and development. For FY2027 it expected at least \$9.5 billion of capital returns and described investment in talent and internal capabilities. The company did not publish a FY2027 R&D or learning budget or deal-level returns for the prospective acquisition pipeline. [C2, pp. 6-7, 11; C5, pp. 4-5.]

For this classroom exercise, assume you are advising Accenture’s board strategy committee after the October 1 release. This advisory assignment is hypothetical; public materials do not establish that the committee posed this question. How should Accenture set evidence and pacing rules for acquisitions while maintaining internal capability investment and shareholder returns?

The decision

Choose a path, or define a fourth:

1. **Continue at the expected pace when opportunities qualify.** Pursue management’s additional approximately \$5 billion FY2027 acquisition expectation, applying deal-specific fit, price and integration tests.
2. **Stage commitments against evidence.** Preserve the acquisition option while requiring defined strategic-fit, client-demand, integration and post-close milestones before later commitments.
3. **Shift some marginal investment toward internal capability or returns.** Emphasize internal R&D, talent development, ecosystem partnerships or capital returns when they present stronger evidence than a prospective deal.

These alternatives are classroom choices, not disclosed company proposals. The approximately \$3 billion shifted Cyber OT amount and the additional approximately \$5 billion imply roughly \$8 billion of FY2027 acquisition activity. The presentation calls this an estimate that includes the

shifted transactions; the amounts are rounded, depend on regulatory timing and opportunities, and are not a binding spend authorization. Do not count \$3 billion + \$5 billion + \$8 billion. [C2, pp. 2-3, 11, 13; C5, p. 7.]

The question is how to govern prospective capability investment when management presents acquisitions, internal capability spending and shareholder returns as concurrent priorities. The public record does not establish a fixed funding ceiling or a zero-sum trade-off among them.

Multiple investment channels

Management described acquisitions as a way to add capabilities, scale in high-growth areas and deepen expertise. FY2026 included 17 acquisitions for about \$4.9 billion, compared with \$1.5 billion across 23 acquisitions in FY2025. These are issuer-reported amounts for different years, not evidence that acquisition count or spending predicts value creation. [C2, pp. 6-7; C3, Item 1, p. 3; C5, p. 4.]

Accenture also invested internally. Management reported \$1 billion each in FY2026 R&D and learning/development, 46 million learning hours and approximately 110,000 AI and data professionals. These measures show activity and workforce scale; they do not disclose proficiency, utilization, client monetization or marginal returns. No FY2027 dollar budgets for R&D or learning were provided in the reviewed cutoff materials. [C2, pp. 6-7; C5, p. 4.]

The latest results offered encouraging but bounded demand signals. Accenture reported a new high of 141 client bookings worth at least \$100 million each in Q4 FY2026. This is a count of quarterly bookings, not their combined value, backlog, recognized revenue or cash. Management said bookings with eight emerging AI and data partners grew more than threefold and revenue with those partners more than doubled; it did not report those measures as total AI business bookings or revenue. [C1, p. 1; C5, p. 4.]

Outlook and counterweights

For FY2027, management expected revenue growth of 3%-6% in local currency, an operating margin of 15.9%-16.1%, operating cash flow of \$11.9-\$12.7 billion, capital expenditures of \$0.9 billion, and free cash flow of \$11.0-\$11.8 billion. It expected at least \$9.5 billion in total capital returns. On the call, management described at least \$5.5 billion of share repurchases plus a dividend increase. Separately, the release reported approximately \$6.9 billion of remaining repurchase authorization, including \$6 billion approved in September. The authorization is capacity, not an additional capital-return commitment. All FY2027 figures are management outlooks, not results. [C1, pp. 6-7; C2, p. 11; C5, pp. 5, 11.]

Management expected acquisitions to contribute 2%-2.5% to FY2027 revenue growth. It said the final acquisition amount depended on the “right opportunities and timing.” That expectation does not disclose specific targets, purchase prices or standalone returns. [C2, pp. 11-13; C5, p. 7.]

The company also identified risks. Its release listed possible AI-related demand displacement, investments that fail to deliver expected benefits, competition, talent and skill alignment, and acquisition/integration execution. On the call, management described pricing as stable overall in FY2026 but lower in many areas in Q4, and expected intense competition to continue. These are disclosed risks and management commentary; they do not establish that current demand or returns are failing. [C1, pp. 8-9; C2, pp. 13-14.]

Selected financial and investment evidence

Measure	FY2026 actual / management report	FY2027 outlook	Source and interpretation
Revenue growth, local currency	5%	3%-6%	FY2027 is management guidance. [C1, pp. 1, 7.]
Free cash flow	\$11.6bn	\$11.0-\$11.8bn	Consolidated/company measure; not project-level available capital. [C1, pp. 6-7.]
Capital returned	\$11.5bn	At least \$9.5bn	FY2027 call described $\geq$ \$5.5bn buybacks plus a dividend increase. [C1, pp. 6-7; C2, p. 11.]
Acquisition activity	\$4.9bn across 17 acquisitions	Approx. \$8bn indicated, including ~\$3bn shifted plus “another” ~\$5bn	Rounded estimate/expectation; opportunity- and timing-dependent. [C2, pp. 2-3, 11-13; C5, pp. 4, 7.]
Internal investment	\$1bn R&D; \$1bn learning/development	No FY2027 dollar budgets disclosed	Historical amounts are not future commitments or returns. [C2, pp. 6-7; C5, p. 4.]
Repurchase authority	Approx. \$6.9bn remaining	Not a separate FY2027 return amount	Authorization capacity must not be added to return guidance. [C1, p. 6.]

The figures describe management’s plan and the company’s consolidated results. They do not supply an acquisition hurdle rate, target pipeline, integration cost, FY2027 internal-investment budget or proof that each capital use competes for the same dollars.

Prepare your recommendation

Write a short committee memo that:

- selects a path and states the strongest counterargument;
- distinguishes the shifted ~\$3 billion from the additional ~\$5 billion and explains the approximate \$8 billion total without double-counting;
- identifies what evidence should determine whether to buy, build, partner or return capital;
- proposes observable milestones that would change the pace or direction of investment; and
- states which missing data are most important before committing to a specific deal.

Any numerical threshold you introduce is a **classroom assumption**, not a disclosed Accenture target. The case does not ask you to infer a binding funding constraint or to turn bookings, AI-partner growth, training hours or workforce size into earnings or returns.

Selected sources

C1 is Accenture's FY2026 Q4/full-year results release, furnished Oct. 1, 2026; C2 is the same-day earnings-call transcript; C3 is the FY2025 Form 10-K; C4 is the FY2026 Q3 Form 10-Q; and C5 is the separate FY2026 Q4 earnings presentation. Accession details, direct links and exact source locators appear in the source register. The information cutoff is Oct. 3, 2026; later disclosures are excluded.